Wednesday, July 8, 2026

Patent intelligence · US

US 8871907

Glycosylated immunoglobulin and immunoadhesin comprising the same

granted A61KA61K38/1774
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 8
Applicant portfolio 127
Patent details — US 8871907

Quick answer

US 8871907 (Glycosylated immunoglobulin and immunoadhesin comprising the same) is held by KOREA PRIME PHARM CO., LTD.. Status: granted. Granted Oct 28, 2014. Expires Oct 23, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K38/1774

More from KOREA PRIME PHARM CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12404275

    Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof

    PrimeGene (Beijing) Co., Ltd. · Expires Aug 28, 2045

    granted
  2. US 12383582

    Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases

    Prime Merger Sub, LLC · Expires Aug 7, 2045

    granted
  3. US 12377115

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Expires Jul 31, 2045

    granted
  4. US 12365719

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Expires Jul 17, 2045

    granted
  5. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Expires May 29, 2045

    granted
  6. US 12304898

    Quinolyl-containing compound and pharmaceutical composition, and use thereof

    PrimeGene (Beijing) Co., Ltd. · Expires May 15, 2045

    granted
  7. US 12234302

    Chitosan derivatives and methods for preparing the same

    PRIMEX EHF · Expires Feb 20, 2045

    granted
  8. US 12233119

    Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins

    Prime Bio, Inc. · Expires Feb 20, 2045

    granted

Frequently asked questions

What is US patent 8871907?

US 8871907 (Glycosylated immunoglobulin and immunoadhesin comprising the same) is held by KOREA PRIME PHARM CO., LTD.. Status: granted. Granted Oct 28, 2014. Expires Oct 23, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8871907?

KOREA PRIME PHARM CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 127 pharmaceutical patents for this assignee.

When does US 8871907 expire?

Our index shows an expiration date of Oct 23, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.